Related Experiment Video
Updated: May 9, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates
Felipe V Pereira1, Denise C Arruda, Carlos R Figueiredo
1Laboratório de Imunobiologia do Câncer, Departamento de Microbiologia, Imunologia e Parasitologia, Escola Paulista de Medicina (EPM-UNIFESP), Universidade Federal de São Paulo, São Paulo/SP, Brazil.
Objective:
Available chemotherapy presents poor control over the development of metastatic melanoma. FTY720 is a compound already approved by the Food and Drug Administration for the treatment of patients with multiple sclerosis. It has also been observed that FTY720 inhibits tumor growth in vivo (experimental models) and in vitro (animal and human tumor cells). The aim of this study was to evaluate the effects of FTY720 on a metastatic melanoma model and in tumor cell lines.
Methods:
We analyzed FTY720 efficacy in vivo in a syngeneic murine metastatic melanoma model, in which we injected tumor cells intravenously into C57BL/6 mice and then treated the mice orally with the compound for 7 days. We also treated mice and human tumor cell lines with FTY720 in vitro, and cell viability and death pathways were analyzed.
Results:
FTY720 treatment limited metastatic melanoma growth in vivo and promoted a dose-dependent decrease in the viability of murine and human tumor cells in vitro. Melanoma cells treated with FTY720 exhibited characteristics of programmed cell death, reactive oxygen species generation, and increased β-catenin expression. In addition, FTY720 treatment resulted in an immunomodulatory effect in vivo by decreasing the percentage of Foxp3+ cells, without interfering with CD8+ T cells or lymphocyte-producing interferon-gamma.
Conclusion:
Further studies are needed using FTY720 as a monotherapy or in combined therapy, as different types of cancer cells would require a variety of signaling pathways to be extinguished.
Insights
FTY720, an approved drug, effectively inhibited metastatic melanoma growth in preclinical models. It reduced tumor cell viability and modulated immune responses, suggesting potential as a melanoma treatment.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Current chemotherapy options offer limited control over metastatic melanoma progression.
- FTY720 (siponimod) is an FDA-approved drug for multiple sclerosis with demonstrated in vitro and in vivo anti-tumor properties.
Purpose of the Study:
- To investigate the efficacy of FTY720 in a murine model of metastatic melanoma.
- To evaluate the direct effects of FTY720 on melanoma cell lines in vitro.
Main Methods:
- In vivo studies involved administering FTY720 orally to C57BL/6 mice with established metastatic melanoma.
- In vitro studies assessed FTY720's impact on murine and human melanoma cell lines, analyzing cell viability and death pathways.
- Immunomodulatory effects were evaluated by analyzing immune cell populations (Foxp3+, CD8+ T cells, interferon-gamma producing lymphocytes).
Main Results:
- FTY720 significantly limited metastatic melanoma growth in vivo and reduced tumor cell viability in a dose-dependent manner in vitro.
- FTY720 induced programmed cell death, increased reactive oxygen species, and upregulated β-catenin expression in melanoma cells.
- In vivo, FTY720 demonstrated immunomodulatory effects by decreasing regulatory T cells (Foxp3+) without impacting cytotoxic CD8+ T cells or interferon-gamma production.
Conclusions:
- FTY720 exhibits potent anti-melanoma activity, warranting further investigation as a potential monotherapy or in combination treatments.
- Additional research is necessary to determine optimal therapeutic strategies, considering the diverse signaling pathways targeted in different cancer types.
